BG107752A - Соли на изотиазол-4-карбоксамид и тяхното приложение като антихиперпролиферативни агенти - Google Patents

Соли на изотиазол-4-карбоксамид и тяхното приложение като антихиперпролиферативни агенти Download PDF

Info

Publication number
BG107752A
BG107752A BG107752A BG10775203A BG107752A BG 107752 A BG107752 A BG 107752A BG 107752 A BG107752 A BG 107752A BG 10775203 A BG10775203 A BG 10775203A BG 107752 A BG107752 A BG 107752A
Authority
BG
Bulgaria
Prior art keywords
salt
isothiazole
ray diffraction
bromo
ureido
Prior art date
Application number
BG107752A
Other languages
Bulgarian (bg)
English (en)
Inventor
Thomas G. Gant
Glenn R. Williams
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG107752A publication Critical patent/BG107752A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BG107752A 2000-11-28 2003-04-22 Соли на изотиазол-4-карбоксамид и тяхното приложение като антихиперпролиферативни агенти BG107752A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25351300P 2000-11-28 2000-11-28
PCT/IB2001/002193 WO2002044158A1 (en) 2000-11-28 2001-11-19 Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents

Publications (1)

Publication Number Publication Date
BG107752A true BG107752A (bg) 2004-01-30

Family

ID=22960587

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107752A BG107752A (bg) 2000-11-28 2003-04-22 Соли на изотиазол-4-карбоксамид и тяхното приложение като антихиперпролиферативни агенти

Country Status (50)

Country Link
US (1) US6831091B2 (ru)
EP (1) EP1337521B1 (ru)
JP (2) JP2004514714A (ru)
KR (2) KR20050116401A (ru)
CN (1) CN1231474C (ru)
AP (1) AP2001002358A0 (ru)
AR (1) AR031512A1 (ru)
AT (1) ATE340786T1 (ru)
AU (2) AU2002214204B2 (ru)
BG (1) BG107752A (ru)
BR (1) BR0115621A (ru)
CA (1) CA2430065C (ru)
CR (1) CR6963A (ru)
CY (1) CY1106240T1 (ru)
CZ (1) CZ20031315A3 (ru)
DE (1) DE60123461T2 (ru)
DK (1) DK1337521T3 (ru)
DO (1) DOP2001000288A (ru)
EA (1) EA005859B1 (ru)
EC (1) ECSP034628A (ru)
EE (1) EE200300247A (ru)
ES (1) ES2271086T3 (ru)
GE (1) GEP20053652B (ru)
GT (1) GT200100237A (ru)
HK (1) HK1059085A1 (ru)
HN (1) HN2001000268A (ru)
HR (1) HRP20030408A2 (ru)
HU (1) HUP0302553A3 (ru)
IL (1) IL155371A0 (ru)
IS (1) IS6788A (ru)
MA (1) MA26960A1 (ru)
MX (1) MXPA03004714A (ru)
MY (1) MY136686A (ru)
NO (1) NO325187B1 (ru)
NZ (1) NZ525788A (ru)
OA (1) OA12532A (ru)
PA (1) PA8533801A1 (ru)
PE (1) PE20020591A1 (ru)
PL (1) PL362079A1 (ru)
PT (1) PT1337521E (ru)
SI (1) SI1337521T1 (ru)
SK (1) SK5862003A3 (ru)
SV (1) SV2002000748A (ru)
TN (1) TNSN01167A1 (ru)
TW (1) TWI287542B (ru)
UA (1) UA74221C2 (ru)
UY (1) UY27039A1 (ru)
WO (1) WO2002044158A1 (ru)
YU (1) YU36403A (ru)
ZA (1) ZA200303341B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (ru) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Производные изотиазола, способ их получения, фармацевтическая композиция и способ лечения гиперпролиферативного заболевания у млекопитающего
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
EP1527071A1 (en) * 2002-07-25 2005-05-04 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
MXPA05001958A (es) * 2002-08-19 2005-04-28 Pfizer Prod Inc Terapia de combinacion para enfermedades hiperproliferativas.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
ME00294B (me) 2003-07-23 2011-05-10 Bayer Pharmaceuticals Corp Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti
UA81365C2 (en) * 2003-10-27 2007-12-25 Merck & Co Inc Ccr-2 antagonist salt, method for modulation of chemokine receptor activity, method for treating (variants) and pharmaceutical composition
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
CA2564325A1 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
TW200538104A (en) * 2004-05-17 2005-12-01 Pfizer Prod Inc Phenyl derivatives for the treatment of abnormal cell growth
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0713425A2 (pt) 2006-06-16 2012-03-13 H. Lundbeck A/S composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
EP2596026B1 (en) 2010-07-23 2020-04-08 Trustees of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
DK2968650T3 (en) 2013-03-14 2019-03-11 Panoptica Inc EYE PHARMACEUTICAL FORMULATIONS FOR THE POSTERIOR EYE SEGMENT
EP3193867B1 (en) * 2014-09-17 2021-01-20 PanOptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye
WO2024140850A1 (zh) * 2022-12-28 2024-07-04 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (ru) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Производные изотиазола, способ их получения, фармацевтическая композиция и способ лечения гиперпролиферативного заболевания у млекопитающего

Also Published As

Publication number Publication date
YU36403A (sh) 2006-08-17
ATE340786T1 (de) 2006-10-15
NO20032388L (no) 2003-07-18
US6831091B2 (en) 2004-12-14
AR031512A1 (es) 2003-09-24
PE20020591A1 (es) 2002-07-06
JP4971946B2 (ja) 2012-07-11
SV2002000748A (es) 2002-12-02
HRP20030408A2 (en) 2003-08-31
GT200100237A (es) 2002-07-03
DOP2001000288A (es) 2002-12-15
EP1337521A1 (en) 2003-08-27
KR20030059275A (ko) 2003-07-07
EA005859B1 (ru) 2005-06-30
IS6788A (is) 2003-04-14
HK1059085A1 (en) 2004-06-18
NO325187B1 (no) 2008-02-11
JP2004514714A (ja) 2004-05-20
AU1420402A (en) 2002-06-11
ES2271086T3 (es) 2007-04-16
KR20050116401A (ko) 2005-12-12
EP1337521B1 (en) 2006-09-27
PT1337521E (pt) 2006-12-29
OA12532A (en) 2006-06-02
MA26960A1 (fr) 2004-12-20
SK5862003A3 (en) 2004-05-04
AU2002214204B2 (en) 2007-05-24
WO2002044158A1 (en) 2002-06-06
IL155371A0 (en) 2003-11-23
NZ525788A (en) 2004-11-26
HUP0302553A3 (en) 2009-03-30
HUP0302553A2 (hu) 2003-11-28
JP2008056692A (ja) 2008-03-13
EA200300424A1 (ru) 2003-10-30
CN1476439A (zh) 2004-02-18
CR6963A (es) 2003-11-25
MY136686A (en) 2008-11-28
HN2001000268A (es) 2002-01-30
TNSN01167A1 (fr) 2005-11-10
TWI287542B (en) 2007-10-01
GEP20053652B (en) 2005-11-10
DE60123461T2 (de) 2007-02-15
ECSP034628A (es) 2003-07-25
MXPA03004714A (es) 2003-08-19
BR0115621A (pt) 2003-09-02
CN1231474C (zh) 2005-12-14
CY1106240T1 (el) 2011-06-08
UA74221C2 (ru) 2005-11-15
NO20032388D0 (no) 2003-05-27
CZ20031315A3 (cs) 2004-04-14
CA2430065A1 (en) 2002-06-06
ZA200303341B (en) 2004-04-30
PA8533801A1 (es) 2002-10-31
DK1337521T3 (da) 2007-01-29
CA2430065C (en) 2008-05-20
SI1337521T1 (sl) 2006-12-31
US20020151573A1 (en) 2002-10-17
AP2001002358A0 (en) 2001-12-31
UY27039A1 (es) 2002-07-31
PL362079A1 (en) 2004-10-18
DE60123461D1 (de) 2006-11-09
EE200300247A (et) 2003-10-15

Similar Documents

Publication Publication Date Title
BG107752A (bg) Соли на изотиазол-4-карбоксамид и тяхното приложение като антихиперпролиферативни агенти
AU2002214204A1 (en) Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents
EP1187826B1 (en) Heterocyclic derivatives useful as anticancer agents
JP6231556B2 (ja) Ｎ−［５−（３，５−ジフルオロ−ベンジル）−１ｈ−インダゾール−３−イル］−４−（４−メチル−ピペラジン−１−イル）−２−（テトラヒドロ−ピラン−４−イルアミノ）−ベンズアミドの調製方法
TWI620748B (zh) 氨基噻唑化合物及其用途
BG65180B1 (bg) Тиенопиридинови производни, полезни като противоракови средства
UA75482C2 (en) Salts of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methylpyridine-3-yloxy)phenylamino]quinozaline -6-yl}alyl)acetamide, a method for the preparation and use thereof for the treatment of cancer
JP2017128612A (ja) Ａｒｒｙ−３８０の多形体、選択的ｅｒｂｂ２（ｈｅｒ２）阻害剤、およびそれらを含有する薬学的組成物
UA60363C2 (ru) Безводные и моногидратные формы n-(3-этинилфениламино)-6,7-бис(2-метоксиэтокси)-4- хиназолинамина мезилата
PT1636215E (pt) Furazanobenzimidazoles
JP2020523348A (ja) プロテインキナーゼ阻害剤としてのアミノチアゾール化合物
WO2024008129A1 (zh) 作为kat6抑制剂的化合物
TW202220982A (zh) 噻唑化合物作為蛋白質激酶抑制劑
CN100471841C (zh) (2-甲酰胺基)(3-氨基)噻吩化合物
EP3740208A1 (en) Compounds for treating rac-gtpase mediated disorder
WO2014082230A1 (zh) 吡咯并三嗪类衍生物、其制备方法及其在医药上的应用